Your browser doesn't support javascript.
loading
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W; Husby, Simon; Grønbæk, Kirsten; Jerkeman, Mats; Laurell, Anna; Räty, Riikka; Elonen, Erkki; Andersen, Niels Smedegaard; Brown, Peter deNully; Kimby, Eva; Bentzen, Hans; Sundström, Christer; Ehinger, Mats; Karjalainen-Lindsberg, Marja-Liisa; Delabie, Jan; Ralfkiær, Elisabeth; Fagerli, Unn-Merete; Nilsson-Ehle, Herman; Lauritzsen, Grete Fossum; Kuittinen, Outi; Niemann, Carsten; Geisler, Christian Hartman.
Afiliação
  • Kolstad A; Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway. Electronic address: arnek@ous-hf.no.
  • Pedersen LB; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Eskelund CW; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Husby S; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Grønbæk K; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Jerkeman M; Department of Oncology, Skåne University Hospital, Lund, Sweden.
  • Laurell A; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Räty R; Department of Hematology and Oncology, Helsinki University Central Hospital, Helsinki, Finland.
  • Elonen E; Department of Hematology and Oncology, Helsinki University Central Hospital, Helsinki, Finland.
  • Andersen NS; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Brown PD; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden.
  • Bentzen H; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Sundström C; Department of Pathology, Uppsala University Hospital, Uppsala, Sweden.
  • Ehinger M; Department of Pathology, Skåne University Hospital, Lund, Sweden.
  • Karjalainen-Lindsberg ML; Department of Pathology, Helsinki Central University Hospital, Helsinki, Finland.
  • Delabie J; Department of Pathology, Oslo University Hospital, Oslo, Norway.
  • Ralfkiær E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Fagerli UM; Department of Oncology, St Olavs University Hospital, Trondheim, Norway.
  • Nilsson-Ehle H; Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Lauritzsen GF; Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.
  • Kuittinen O; Department of Oncology, Oulu University Hospital, Oulu, Finland.
  • Niemann C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Geisler CH; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Biol Blood Marrow Transplant ; 23(3): 428-435, 2017 Mar.
Article em En | MEDLINE | ID: mdl-28039078
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasia Residual / Transplante de Células-Tronco Hematopoéticas / Linfoma de Célula do Manto / Rituximab Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasia Residual / Transplante de Células-Tronco Hematopoéticas / Linfoma de Célula do Manto / Rituximab Idioma: En Ano de publicação: 2017 Tipo de documento: Article